Spero therapeutics announces fourth quarter and full year 2024 operating results and provides a business update

Cambridge, mass., march 27, 2025 (globe newswire) -- spero therapeutics, inc. (nasdaq: spro), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (mdr) bacterial infections, today announced financial results for the fourth quarter and full year ended december 31, 2024, and provided a business update.
SPRO Ratings Summary
Quant
SPRO Quant Ranking
Sector
Industry
Quant Rating
Quant Score